To confirm that SHIP1 inhibition hyperactivates the PI3K/AKT signaling pathway in CLL, we analyzed AKT S473-phosphorylation levels and, as expected45, found significantly increased activation upon SHIP1 inhibition (Fig. 2d). The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.